Login to Your Account

Nymox heads toward filings, again, after long-term fexapotide win in BPH

By Marie Powers
News Editor

Tuesday, October 11, 2016

Although the development program for fexapotide was encumbered by previous failure and threatened to go into extra innings – Nymox Pharmaceutical Corp. completed seven U.S. phase III trials, by its count.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription